NTL HEALTHCARE Pitches AI Cervical Screening Pilots in South Africa
PRETORIA – November 05, 2026 -- NTL HEALTHCARE proposed local clinical validation and hospital pilots in South Africa for CerviCARE AI, an on-device cervical screening tool that works offline and analyzes images in approximately five seconds.
NTL cites 98% sensitivity for high-grade lesions in a 2024 study
Executive Vice President Dr. Jake Byun presented the solution at the 2026 Korea-South Africa Future Dialogue, co-hosted by the Korean Embassy and the Korea-Africa Foundation. He said NTL's cervical screening expertise dates to 1996 and covers more than eight million cases. A 2024 Scientific Reports study reported 98% sensitivity for high-grade lesions.
Byun said CerviCARE AI could support assessment, referral, treatment and follow-up after positive HPV results. It would not replace HPV testing or clinical judgment.